BMS Returns TIGIT Bispecific To Agenus Amid Pipeline Reshuffle
Agenus said in an SEC filing that Bristol Myers Squibb was sending back AGEN1777, which entered into Phase II development earlier this year.
Agenus said in an SEC filing that Bristol Myers Squibb was sending back AGEN1777, which entered into Phase II development earlier this year.